Background and Aims: Chromophobe renal cell carcinoma (chRCC) is the third common pathological subtype in renal cancers. However, the underlying mechanisms of specific genetic characteristics of chRCC are currently unclear. In this study, protein expression profiles, gene ontology (GO), and survival plots were provided by integrated bioinformatics analysis to investigate key genes associated with the mechanism of tumorigenesis and prognosis of chRCC.Methods: The chRCC data set of gene expression profiles and clinical data were obtained from the gdc‐client (https://portal.gdc.cancer.gov) deposited on The Cancer Genome Atlas (TCGA) data portal. Differentially expressed genes (DEGs) in chRCC, compared with normal samples, were analyzed by R packages “DESeq2,” “edgeR,” and “limma.” Heat maps, volcano plots, and principal component analysis (PCA) were performed for integrated analyses. GUniGO, mutant analysis, and survival plots were performed by R packages. A protein–protein interaction (PPI) network was generated and analyzed by R packages, online String software, and Cytoscape software. Survival analysis and gene expressing comparison in tumor and normal samples were used to detect the core genes of chRCC. Furthermore, the top interacting proteins were reanalyzed.Results: A total of 306 upregulated genes and 678 downregulated genes were identified by a Venn diagram. Ten hub genes were extracted from PPI network. Furthermore, Alpha‐2‐Heremans‐Schmid‐glycoprotein (AHSG), one of 10 hub genes, was found to be associated with chRCC, and had a big difference in expression between survival and dead events. AHSG could predict potential prognostic and may be a diagnostic biomarker in chRCC.Conclusion: This study illustrated that AHSG may be a potential therapeutic target and prognostic genetic marker for chRCC.
1 January 2024 in International Journal of Surgical Oncology
Background: Uterine corpus endometrial carcinoma (UCEC) ranks as a predominant tumor within the female reproductive system. Matrine, the chief active constituent of Compound Kushen Injection, exhibits antibacterial, antiviral, anti‐inflammatory, and antitumor effects. On the basis of previous research studies, this study utilized bioinformatics and network pharmacology approaches to investigate matrine’s anti‐UCEC potential, establishing a theoretical groundwork for subsequent mechanistic studies.Objective: Differentially expressed genes (DEGs) from the TCGA‐UCEC database were processed using R packages. Potential targets of matrine were identified via PubChem, SwissTargetPrediction, and BindingDB. The hub genes were identified through cytoHubba from the overlapping genes of matrine targets and UCEC DEGs. These genes were then subjected to cancer immune infiltration analysis, assessed with the R package “ggbeeswarm,” and validated by molecular docking studies.Results: We identified 28 potential drug–disease interaction genes and narrowed down to 10 hub genes. Notably, CDH1 and EPCAM were significantly differentially expressed between tumor and normal samples. Their expression levels correlated positively with multiple immune cells types. Molecular docking revealed significant interactions between CDH1, EPCAM, and matrine.Conclusions: These findings suggest that matrine’s anti‐UCEC activity may involve interactions with CDH1 and EPCAM. Advancing UCEC therapy based on these interactions could improve tumor diagnosis and treatment, including for UCEC.